Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ekaterini Kotsopoulou"'
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 20, Iss , Pp 675-687 (2021)
The majority of CD19-directed CAR T cell products are manufactured using an autologous process. Although using a patient's leukapheresis reduces the risks of rejection, it introduces variability in starting material composition and the presence of ce
Externí odkaz:
https://doaj.org/article/4c49ad44a5624891a02636961b44ab06
Autor:
Xiaonan Wang, Carlotta Peticone, Ekaterini Kotsopoulou, Berthold Göttgens, Fernando J Calero-Nieto
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Chimeric antigen receptor (CAR) T-cell adoptive therapy is set to transform the treatment of a rapidly expanding range of malignancies. Although the activation process of normal T cells is well characterized, comparatively little is known about the a
Externí odkaz:
https://doaj.org/article/87b47f7817ff41798e7fcb47581372fc
Autor:
Leila Mekkaoui, Farhaan Parekh, Ekaterini Kotsopoulou, David Darling, Glenda Dickson, Gordon W. Cheung, Lucas Chan, Kirsty MacLellan-Gibson, Giada Mattiuzzo, Farzin Farzaneh, Yasuhiro. Takeuchi, Martin Pule
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 11, Iss , Pp 155-165 (2018)
Lentiviral vectors (LVs) have recently witnessed an increasing demand in research and clinical applications. Their current purification processes represent the main bottleneck in their widespread use, as the methods used are cumbersome and yield low
Externí odkaz:
https://doaj.org/article/fa0e0c7804034ed983ca5258b74e7dce
Autor:
Berthold Göttgens, Fernando J Calero-Nieto, Carlotta Peticone, Xiaonan Wang, Ekaterini Kotsopoulou
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Oncoimmunology
article-version (VoR) Version of Record
Oncoimmunology
article-version (VoR) Version of Record
Chimeric antigen receptor (CAR) T-cell adoptive therapy is set to transform the treatment of a rapidly expanding range of malignancies. Although the activation process of normal T cells is well characterized, comparatively little is known about the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69be0acbfe2d3774004ba34a68825acc
https://www.repository.cam.ac.uk/handle/1810/315151
https://www.repository.cam.ac.uk/handle/1810/315151
Autor:
Glenda Dickson, Lucas Chan, Giada Mattiuzzo, Yasuhiro Takeuchi, Kirsty MacLellan-Gibson, Martin Pule, Gordon Weng-Kit Cheung, Leila Mekkaoui, Ekaterini Kotsopoulou, Farhaan Parekh, David Darling, Farzin Farzaneh
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 11, Iss, Pp 155-165 (2018)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Lentiviral vectors (LVs) have recently witnessed an increasing demand in research and clinical applications. Their current purification processes represent the main bottleneck in their widespread use, as the methods used are cumbersome and yield low
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bea27b08256f34949c2a29c08255e2b
http://www.sciencedirect.com/science/article/pii/S2329050118301049
http://www.sciencedirect.com/science/article/pii/S2329050118301049
Autor:
Vijay G R Peddareddigari, Simon Thomas, Jim Faulkner, Sonja Zweegman, Tobias Menne, Ekaterini Kotsopoulou, Lydia Lee, Shaun Cordoba, Martin Pule, Virginie Cerec, Kwee Yong, Nushmia Z. Khokhar, Jim Cavet, Muhammad Al-Hajj, Rakesh Popat
Publikováno v:
Blood. 134:3112-3112
Introduction: Chimeric antigen receptor (CAR) T cell therapies directed against B cell maturation antigen (BCMA) have shown significant activity in patients with RRMM, however single antigen targeting with CAR-T cells can result in antigen negative r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::694331aef57a5c0e4e2b7dca060dc092
https://doi.org/10.1182/blood-2019-126689
https://doi.org/10.1182/blood-2019-126689
Autor:
Vijay G R Peddareddigari, Martin Pule, Muhammad Al-Hajj, Robert T. Chen, Nushmia Z. Khokhar, Maria A V Marzolini, Simon Thomas, Kirit M. Ardeshna, Wendy Osborne, Jane Norman, Maud Jonnaert, Jim Faulkner, Ekaterini Kotsopoulou
Publikováno v:
Blood. 134:246-246
Introduction: CD 19 CAR T cell therapies have shown significant activity in patients with r/r DLBCL, however relapses due to CD19 loss or PDL1 upregulation are common. In this study, we are evaluating the safety and efficacy of AUTO3, a CAR T cell th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::880c4fa04a72aea9f9ae4d37fe3fa0dd
https://doi.org/10.1182/blood-2019-122724
https://doi.org/10.1182/blood-2019-122724
Autor:
Vijay G R Peddareddigari, Liz Clark, Shaun Cordoba, Paul Veys, Kanchan Rao, Robert Wynn, Ajay Vora, Martin Pule, Muhammad Al-Hajj, Persis Amrolia, Rachael Hough, Ekaterini Kotsopoulou, Robert Chiesa, Denise Bonney, Nushmia Z. Khokhar, Shimobi Onuoha
Publikováno v:
Blood. 134:2620-2620
Introduction CAR T-cell therapies directed against CD19 or CD22 have shown remarkable activity in r/r B-ALL but relapse due to target antigen down-regulation/loss has been the major cause of treatment failure. To address this, we developed AUTO3, a C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e8726449c26afc94aa4a8ac8bfa6e00
https://doi.org/10.1182/blood-2019-123424
https://doi.org/10.1182/blood-2019-123424
Autor:
Ekaterini Kotsopoulou, Paul Veys, Nushmia Z. Khokhar, Vijay G R Peddareddigari, Ajay Vora, Denise Bonney, Martin Pule, Shaun Cordoba, Persis Amrolia, Muhammad Al-Hajj, Rachael Hough, Robert Wynn, Shimobi Onuoha, Robert Chiesa, Kanchan Rao
Publikováno v:
Blood. 132:279-279
Introduction CAR T-cell therapies directed against CD19 or CD22 antigens have shown significant activity in pediatric patients with r/r B-ALL. Whilst complete response (CR) rates of 70‒90% have been observed, relapse due to target antigen downregul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75b183c22b2867798f8d74a2071317fa
https://doi.org/10.1182/blood-2018-99-118616
https://doi.org/10.1182/blood-2018-99-118616
Autor:
George Stephen, Pamela Pegman, James D. Faulkner, Yuen-Ting Chim, Mark Uden, Hella Bosteels, Ekaterini Kotsopoulou, Susannah I. Thornhill
Publikováno v:
Journal of Biotechnology. 146:186-193
Gene amplification methodologies are frequently employed for the generation of large quantities of recombinant proteins in mammalian cells. Although they usually guarantee very high yields, they are very time consuming. In addition, due to the large
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c6e67b5d3cc45fbfe0aa93900dae20d
https://doi.org/10.1016/j.jbiotec.2010.02.004
https://doi.org/10.1016/j.jbiotec.2010.02.004